Scopus
Development and validation of a rapid LC-MS/MS method for methylphenidate, atomoxetine, and their metabolites with application to pediatric pharmacokinetics
Journal of Pharmaceutical and Biomedical Analysis · Nisan 2026
Makale Bilgileri
DergiJournal of Pharmaceutical and Biomedical Analysis
Yayın TarihiNisan 2026
Cilt / Sayfa271
Scopus ID2-s2.0-105025096411
Özet
Therapeutic drug monitoring of attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy is challenged by substantial interindividual variability and the lack of rapid, multiplex analytical platforms. We developed and validated a fast, integrated 5-minute LC–MS/MS assay for the simultaneous quantification of stimulant (methylphenidate, ritalinic acid) and non-stimulant (atomoxetine, 4-hydroxy-atomoxetine) ADHD medications in human serum. The method employs a single-step protein precipitation and requires only 200 µL of serum. Validation demonstrated excellent linearity, precision, accuracy, minimal matrix effects, and robust analyte stability in accordance with FDA and CLSI guidelines. Application to pediatric ADHD patients revealed formulation- and dose-dependent concentration differences for methylphenidate and atomoxetine, along with strong parent–metabolite correlations. No significant associations were observed with age, sex, or body mass index. This rapid and reliable LC–MS/MS platform supports clinically actionable therapeutic drug monitoring and provides a practical framework for personalized ADHD treatment.
Yazarlar (7)
1
Duygu Eryavuz Onmaz
ORCID: 0000-0001-8564-1824
2
Merve Kuz
3
Fatih Hilmi Çetin
4
Halit Necmi Uçar
ORCID: 0000-0002-2706-7454
5
Serhat Türkoğlu
6
Rabia Coban
7
Ali Ünlü
ORCID: 0000-0002-9991-3939
Anahtar Kelimeler
Atomoxetine
LC–MS/MS
Methylphenidate
Pediatric ADHD
Pharmacokinetics
Therapeutic drug monitoring
Kurumlar
Bandırma Onyedi Eylül University
Bandirma Turkey
Diamind Mental Academy
Konya Turkey
Selçuk Tip Fakültesi
Konya Turkey